Pozo-Balado, M MRosado-Sanchez, IMendez-Lagares, GRodriguez-Mendez, M MRuiz-Mateos, EBenhnia, M RMuñoz-Fernandez, M ALeal, MPacheco, Y M2023-01-252023-01-252016-01-22Pozo-Balado MM, Rosado-Sánchez I, Méndez-Lagares G, Rodríguez-Méndez MM, Ruiz-Mateos E, Benhnia MR, et al. Maraviroc contributes to the restoration of the homeostasis of regulatory T-cell subsets in antiretroviral-naive HIV-infected subjects. Clin Microbiol Infect. 2016 May;22(5):461.e1-5.http://hdl.handle.net/10668/9764Regulatory T (Treg) cells comprise different functional subsets with different CCR5 expression. Treg homeostasis is disrupted by HIV but the effect of treatment has barely been explored. In a longitudinal design, we compared the effect of a maraviroc-containing (n = 9) or sparing (n = 12) therapy in antiretroviral-naive HIV-positive participants on peripheral FoxP3(low) CD45RA(+) (nTreg), FoxP3(high) CD45RA(-) (eTreg) and FoxP3(low) CD45RA(-) (non-Treg) cells. Maraviroc significantly reduced all subsets in the short-term and, except for nTreg cells, also normalized them in the long-term. The correlation between eTreg cells and CD4 counts, lost before treatment, was only restored by maraviroc. The differential effect of maraviroc on Treg subsets contributes to understanding its immunomodulatory effects.enCCR5HIVRegulatory T-cellseffector-Treghomeostasismaravirocnaive-Tregnon-TregCCR5 Receptor AntagonistsCD4 Lymphocyte CountCyclohexanesForkhead Transcription FactorsHIV InfectionsHomeostasisHumansImmunophenotypingLeukocyte Common AntigensLongitudinal StudiesMaravirocT-Lymphocyte SubsetsT-Lymphocytes, RegulatoryTriazolesresearch article26806257Restricted AccessCélulasMaravirocTerapéuticaVIHComprensiónHomeostasisRecuento de linfocito CD410.1016/j.cmi.2015.12.0251469-0691http://www.clinicalmicrobiologyandinfection.com/article/S1198743X16000185/pdf